# US 2015/0147335 A1 · Use of TNFalpha Antibody for Treatment of Hidradenitis Suppurativa (HS)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0147335 A1
- Document ID: US20150147335A1
- Status: Published application
- Kind: A1
- Application number: 14/289,115
- Filed: 2014-05-28
- Published: 2015-05-28
- Earliest claimed: 2010-06-03
- Assignees: AbbVie Biotechnology Ltd.
- Applicants: AbbVie Biotechnology, Ltd.
- Inventors: Martin M. Okun; Thomas C. Harris
- Web page: https://patentgrep.com/patent/US20150147335A1

## CPC

- C07K 16/241: {Tumor Necrosis Factors}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61M 5/20: Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically (A61M5/142 takes precedence)
- A61P 17/00: Drugs for dermatological disorders
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07K 16/244: {Interleukins [IL]}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/51: Complete heavy chain or Fd fragment, i.e. VH + CH1
- C07K 2317/515: Complete light chain, i.e. VL + CL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides methods, uses and compositions for the treatment of hidradenitis suppurativa. The invention describes methods and uses for treating hidradenitis suppurativa, wherein a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof, is used to treat hidradenitis suppurativa in a subject. Also described are methods for determining the efficacy of a TNFα inhibitor for treating hidradenitis suppurativa in a subject.

## Claims

### Claim at position 1

1-34. (canceled)

### Claim 35

A method for treating a subject having moderate to severe hidradenitis suppurativa (HS), the method comprising:
at week 0 administering a first loading dose of 160 mg of an isolated human anti-TNFα antibody, or antigen binding portion thereof, to the subject, wherein the first loading dose is administered as four 40 mg doses in one day or two 40 mg doses per day over two consecutive days;
at week 2 administering a second loading dose of 80 mg of the human anti-TNFα antibody, or antigen binding portion thereof, to the subject, wherein the second loading dose is administered as two 40 mg doses in one day; and
starting at week 4 administering a treatment dose of 40 mg of the human anti-TNFα antibody, or antigen binding portion thereof, to the subject weekly,
wherein the anti-TNFα antibody, or antigen binding portion thereof, comprises a variable light chain comprising a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 3; a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 5, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 7; and comprises a variable heavy chain comprising a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 4, a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 6, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 8.

### Claim 36 (depends on 35)

The method of claim 35, wherein the subject has HS lesions in at least two distinct anatomic areas prior to treatment.

### Claim 37 (depends on 35)

The method of claim 35, wherein the subject had an inadequate response to, contraindication to, or was intolerant to oral antibiotics for treatment of their HS.

### Claim 38 (depends on 35)

The method of claim 35, wherein the anti-TNFα antibody, or antigen binding portion thereof, is administered subcutaneously.

### Claim 39 (depends on 35)

The method of claim 35, wherein the anti-TNFα antibody, or antigen binding portion thereof, dissociates from human TNFα with a Kd of 1×10−8 M or less and a koff rate constant of 1×10−3 s−1 or less, both determined by surface plasmon resonance, and neutralizes human TNFα cytotoxicity in a standard in vitro L929 assay with an IC50 of 1×10−7 M or less.

### Claim 40 (depends on 35)

The method of claim 35, wherein the anti-TNFα antibody, or antigen binding portion thereof, has a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 1 and a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 2.

### Claim 41 (depends on 35)

The method of claim 35, wherein the anti-TNFα antibody, or antigen binding portion thereof, is adalimumab.

### Claim 42 (depends on 35)

The method of claim 35, wherein anti-TNFα antibody, or antigen binding portion thereof, is administered with at least one additional therapeutic agent.

### Claim 43 (depends on 35)

The method of claim 35, wherein the subject is selected from the group consisting of a subject having HS at Hurley Stage II or III, a subject having an AN count of greater than or equal to 3 at baseline, a subject who is female, a subject who is over 40 years old, a subject who is a smoker, or any combination thereof.

### Claim 44 (depends on 35)

The method of claim 35, wherein the subject achieves an HiSCR at week 12 of the treatment.

### Claim 45 (depends on 35)

The method of claim 35, wherein the subject achieves at least a 30% reduction in skin pain at week 12 of the treatment.

### Claim 46

A method for decreasing the number of inflammatory lesions (AN count) in a subject having moderate to severe hidradenitis suppurativa (HS), said method comprising systemically
at week 0 administering a first loading dose of 160 mg of an isolated human anti-TNFα antibody, or antigen binding portion thereof, to the subject, wherein the first loading dose is administered as four 40 mg doses in one day or two 40 mg doses per day over two consecutive days;
at week 2 administering a second loading dose of 80 mg of the human anti-TNFα antibody, or antigen binding portion thereof, to the subject, wherein the second loading dose is administered as two 40 mg doses in one day; and
starting at week 4 administering a treatment dose of 40 mg of the human anti-TNFα antibody, or antigen binding portion thereof, to the subject weekly,
wherein the anti-TNFα antibody, or antigen binding portion thereof, comprises a variable light chain comprising a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 3; a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 5, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 7; and comprises a variable heavy chain comprising a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 4, a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 6, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 8.

### Claim 47 (depends on 46)

The method of claim 46, wherein the AN count is reduced by at least 50% reduction in the subject relative to baseline AN count.

### Claim 48 (depends on 47)

The method of claim 47, wherein the subject has no increase in an abscess count and/or no increase in a draining fistula count following administration with the anti-TNFα antibody, or antigen binding portion thereof.

### Claim 49 (depends on 46)

The method of claim 46, wherein the subject has no increase in an abscess count and/or no increase in a draining fistula count following administration with the anti-TNFα antibody, or antigen binding portion thereof.

### Claim 50 (depends on 46)

The method of claim 46, wherein the subject has HS lesions in at least two distinct anatomic areas prior to treatment.

### Claim 51 (depends on 46)

The method of claim 46, wherein the subject had an inadequate response to, contraindication to, or was intolerant to oral antibiotics for treatment of their HS.

### Claim 52 (depends on 46)

The method of claim 46, wherein the anti-TNFα antibody, or antigen binding portion thereof, is administered subcutaneously.

### Claim 53 (depends on 46)

The method of claim 46, wherein the anti-TNFα antibody, or antigen binding portion thereof, dissociates from human TNFα with a Kd of 1×10−8 M or less and a koff rate constant of 1×10−3 s−1 or less, both determined by surface plasmon resonance, and neutralizes human TNFα cytotoxicity in a standard in vitro L929 assay with an IC50 of 1×10−7 M or less.

### Claim 54 (depends on 46)

The method of claim 46, wherein the anti-TNFα antibody, or antigen binding portion thereof, has a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 1 and a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 2.

### Claim 55 (depends on 46)

The method of claim 46, wherein the anti-TNFα antibody, or antigen binding portion thereof, is adalimumab.

### Claim 56 (depends on 46)

The method of claim 46, wherein anti-TNFα antibody, or antigen binding portion thereof, is administered with at least one additional therapeutic agent.

### Claim 57 (depends on 46)

The method of claim 46, wherein the subject is selected from the group consisting of a subject having HS at Hurley Stage II or III, a subject having an AN count of greater than or equal to 3 at baseline, a subject who is female, a subject who is over 40 years old, a subject who is a smoker, or any combination thereof.

### Claim 58 (depends on 46)

The method of claim 46, wherein the subject achieves an HiSCR at week 12 of the treatment.

### Claim 59 (depends on 46)

The method of claim 46, wherein the subject achieves at least a 30% reduction in skin pain at week 12 of the treatment.

### Claim 60

A method for treating a subject having moderate to severe hidradenitis suppurativa (HS), the method comprising:
at week 0 subcutaneously administering a first loading dose of 160 mg of adalimumab to the subject, wherein the first loading dose of adalimumab is administered as four 40 mg doses in one day or two 40 mg doses per day over two consecutive days;
at week 2 subcutaneously administering a second loading dose of 80 mg of adalimumab to the subject, wherein the second loading dose of adalimumab is administered as two 40 mg doses in one day; and
starting at week 4 subcutaneously administering a maintenance dose of 40 mg of adalimumab to the subject weekly.

### Claim 61 (depends on 60)

The method of claim 60, further comprising subcutaneously administering to the subject 40 mg of adalimumab biweekly following a weekly maintenance dosing regimen.

### Claim 62 (depends on 60)

The method of claim 60, wherein the subject has HS lesions in at least two distinct anatomic areas prior to treatment.

### Claim 63 (depends on 60)

The method of claim 60, wherein the subject had an inadequate response to, contraindication to, or was intolerant to oral antibiotics for treatment of their HS.

### Claim 64 (depends on 60)

The method of claim 60, wherein the subject is selected from the group consisting of a subject having HS at Hurley Stage II or III, a subject having an AN count of greater than or equal to 3 at baseline, a subject who is female, a subject who is over 40 years old, a subject who is a smoker, or any combination thereof.

### Claim 65 (depends on 60)

The method of claim 60, wherein the subject achieves an HiSCR at week 12 of the treatment.

### Claim 66 (depends on 60)

The method of claim 60, wherein the subject achieves at least a 30% reduction in skin pain at week 12 of the treatment.

### Claim 67 (depends on 60)

The method of claim 60, wherein when a group of patients having moderate to severe HS are treated according to the treatment method of claim 60, statistically significantly more patients in said group achieve at least 30% reduction in pain relative to baseline at week 12 of said treatment, as compared to a group of patients having moderate to severe HS but treated with placebo under the same dosing scheme as in claim 60.

### Claim 68 (depends on 60)

The method of claim 60, wherein when a group of patients having moderate to severe HS are treated according to the treatment method of claim 60, statistically significantly more patients in said group achieve HiSCR at week 12 of said treatment, as compared to a group of patients having moderate to severe HS but treated with placebo under the same dosing scheme as in claim 60.
